CGI-1746

CGI-1746 is a potent, highly selective, and reversible small-molecule inhibitor of Bruton's tyrosine kinase (BTK). Chemically distinct from covalent inhibitors like ibrutinib, CGI-1746 binds to an allosteric pocket that stabilizes BTK in an inactive conformation, providing exceptional specificity for BTK over other Tec-family and Src-family kinases. Originally developed by CGI Pharmaceuticals (later acquired by Gilead Sciences), it has been widely utilized as a research tool to investigate the role of BTK in B-cell receptor signaling and inflammatory diseases such as rheumatoid arthritis. Recent preclinical studies have also explored its potential in oncology, specifically its ability to modulate the tumor microenvironment in solid tumors like renal cell carcinoma by influencing T-regulatory cell differentiation and PD-1 expression on CD8+ T cells.